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INTRODUCTION
The myeloproliferative neoplasms (MPNs) are chronic hematological malignancies that arise in the hematopoietic stem cell (HSC) compartment and share a variable propensity to transform to acute myeloid leukemia. [1] [2] [3] The BCR-ABL-negative 'classic' MPNs are described as falling into three categories: polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). PV and ET are chronic phase disorders with a relatively benign prognosis -major complications include thrombosis and myelofibrotic transformation. PMF is less common and is a more advanced disease. It closely resembles myelofibrotic transformation of PV and ET, and in many cases is likely to represent presentation in accelerated phase of an undiagnosed preexisting ET. 4, 5 Most patients with one of the three classical MPNs harbor phenotypic driver mutations that affect cytokine signaling through JAK family kinases. 6 The most common lesion is an acquired JAK2V617F mutation. [7] [8] [9] [10] With the subsequent discovery of JAK2 exon 12 mutations, it is now clear that the vast majority of PV patients harbor a gain-of-function mutation in JAK2. 11 In ET and PMF, only 50% of patients carry a JAK2 mutation. Of the JAK2 non-mutated patients, approximately 5-10% carry a gain-of-function mutation in THPO receptor (MPL), the gene for the thrombopoietin (THPO) receptor 12 , and a further 70-84% possess mutations in CALR, which encodes an endoplasmic reticulum chaperone. 6, 13 Though multiple different CALR mutations have been described, 2, 6, 13 all are deletions or insertions within exon 9 that results in a +1bp frame shift and thereby generate a protein with a novel Cterminus. Recent structure/function studies have elegantly shown that mutant CALR interacts with the extracellular domain of THPO receptor to activate downstream signaling and that the novel Cterminus is essential for this process. [14] [15] [16] Retroviral studies 14, 17 and transgenic studies 18 (in which mutant CALR cDNA was driven by the H-2K b promoter and Mo-MuLV LTR) have shown that mutant CALR can generate a myeloproliferative phenotype in mice. However, the pathogenetic consequences of expressing mutant CALR in an appropriate cell type-specific manner and at physiological levels are unknown. Here, we describe the generation of knock-in mice expressing the most common form of mutant CALR (52bp deletion) under the control of the mouse CALR locus. were selected. ES clones with correctly targeted alleles (designated CALR fl/+ ) were injected into albino C57BL/6 blastocysts and chimeras were bred with C57BL/6 mice to generate germline heterozygous CALR fl/+ mice. All mice were kept in specific pathogen free conditions and all procedures performed according to UK Home Office regulations. 
MATERIALS AND METHODS

Generation of hematopoietic-specific conditional knock-in mice for
Bone marrow transplantation assays
Single HSC in vitro Cultures
In vitro culture of single E-SLAM HSCs was performed as previously described. 
Statistics
The statistical differences between control and CALR del/+ mice were assessed using a two-tailed, unpaired Student's t-test unless otherwise indicated.
RESULTS
Generation of conditional mutant calreticulin knock-in mice
To study the role of calreticulin mutations in the pathogenesis of MPNs, we generated a conditional knock-in allele in murine ES cells using homologous recombination for the most common CALR mutation (52 bp deletion) ( Figure 1A ). Species-specific differences in codon preferences meant that simply generating an analogous 52bp deletion within the mouse sequence would generate a novel C-terminus substantially different from that seen in ET patients ( Figure 1B) . We therefore adopted a strategy in which the targeted allele (CALR fl ) contains a LoxP site in intron 7, and a PGKNeo-polyA LoxP cassette followed by mouse exon 8 fused with mutant human calreticulin 3' cDNA sequence downstream of exon 9 ( Figure 1A ; supplemental Figure 1A ). This approach allowed the generation of a conditional allele expressing a mutant calreticulin protein with a carboxy-terminal amino acid sequence identical to that found in MPN patients, whilst keeping the were expanded and then subjected to transient Cre expression using a PGK-Cre plasmid. Genomic PCR confirmed the recombination of the allele ( Figure 1E ). RT-PCR was performed on total RNA from ES cells after Cre recombination and the PCR product was cloned and sequenced to demonstrate expression of CALR mRNA with the 52bp deletion ( Figure 1F ; supplemental Figure   1C Figures 2A, B) . By 4 weeks after pIpC, genomic PCR showed recombination in more than 80% of nucleated blood cells (supplemental Figure 2C ).
Mutant CALR RNA expression was confirmed by RT-PCR in bone marrow cells (supplemental Figure 2D ). In HSPCs, transcript levels of mutant CALR were 65-72% (mean 68%) of transcript levels from the WT allele as analysed by fragment analysis (Supplemental Figure 2E ). A reduction in the level of mutant transcripts was also seen using several different expression constructs (supplemental Figure 2F ) and in a previously reported transgenic model, 18 indicating that lower levels of mutant CALR transcripts are not specific to the targeting construct used to generate our knock-in mice, and may instead reflect altered stability associated with the novel 3' sequence.
Levels of the mutant protein in CALR del/del mice were much lower than levels of WT protein in control cells (supplemental Figure 2G) , an observation consistent with the previous demonstration that the mutant protein is unstable 51, 52 and also consistent with the results from a retroviral transplantation model. 17 CALR del/+ mice developed a striking thrombocytosis compared with wild-type littermate controls.
White blood cell (WBC) counts were mildly elevated in some but not all cohorts, and red blood cell (RBC) parameters were not affected ( Figure 2A) . No difference in survival was observed in cohorts maintained for up to 8 months (supplemental Figure 3A) . We also crossed CALR fl/+ mice with VavCre transgenic mice 22 . Similar to results with Mx1Cre, VavCre resulted in high rates of recombination in peripheral blood and mice developed thrombocytosis (supplemental Figure 3B and C).
In JAK2 V617F knock-in mice, platelet reactivity to collage-related peptide (CRP) and thrombin agonists was increased. 23 We therefore studied platelet reactivity to several agonists including CRP, thrombin and ADP, but observed no significant increase in response to any agonist using platelets of the CALR del/+ mice (supplemental Figure 3D ).
Bone marrow cellularity and spleen weight were not significantly affected in CALR del/+ mice 3-4 months after pIpC injection (supplemental Figure 4A and B). Histological analysis of BM from CALR del/+ mice showed megakaryocytic hyperplasia with megakaryocytes displaying large and hyperlobated nuclei and increased clustering ( Figure 2B ). Spleen architecture was not affected, although a degree of extra-medullary hematopoiesis was observed in some cases, and there was no significant increase in reticulin staining in either bone marrow or spleen at this time point ( Figure 2B ; supplemental Figure 4C ). Compared to littermate controls, the bone marrow of CALR del/+ mice contained increased numbers of CFU-MKs ( Figure 2C ) and megakaryocytes ( Figure 2D ) together with reduced numbers of CD71 + Ter119 + erythroblasts ( Figure 2E ). Numbers of myeloerythroid progenitor populations and more mature myeloid cells (Mac1 + Ly6g + ) in the bone marrow were not significantly altered (supplemental Figure 4D ). In the spleen, there was no significant alteration in the proportion of megakaryocytes, myeloid cells or erythroblasts (supplemental Figure 4E ). Taken together, these data demonstrate that CALR del/+ mice displayed a marked thrombocytosis accompanied by increased megakaryopoiesis and compromised erythropoiesis in the bone marrow.
Thrombocytosis in CALR del/+ mice is transplantable
Thrombopoietin (THPO) levels were not raised in CALR del/+ mice and were, if anything, reduced (although this did not reach statistical significance), suggesting that the thrombocytosis was not THPO-driven and was likely to be cell-intrinsic ( Figure 3A ). To confirm this inference, wild-type recipient mice were transplanted with bone marrow cells from CALR del/+ mice 2 months post pIpC.
At both one month and four months after transplant, the level of chimerism was approximately Figure 5B) indicating that thrombocytosis was still evident in the presence of 40% normal hematopoietic cells. These data demonstrate that the thrombocytosis in CALR del/+ mice is transplantable and reflects a bone marrow-cell intrinsic mechanism.
Mutant CALR is associated with increased proliferation of single HSCs in vitro but no selfrenewal advantage in vivo
The bone marrow of CALR del/+ mice contained increased numbers of HSCs, both Lin -Sca1 + cKit + CD150 + CD48 -HSCs ( Figure 4A ) and E-SLAM HSCs (
supplemental Figure 6A ). To examine the effect of mutant CALR on the behaviour of HSCs, we studied the survival and cell division kinetics of single HSCs together with their ability to proliferate and differentiate. 19, 20 Compared to wildtype controls, the proportion of single To investigate the functional consequences of mutant calreticulin on HSCs, competitive bone marrow transplantation was performed using cells from mice at 2 months after pIpC. Figure 4F ), myeloid and lymphoid lineages ( Figure 4G ).
Secondary transplants were performed, and at 4 months after transplantation, CALR del/+ cells again showed no significant repopulation advantage ( Figure 4H ). Together, these data show that CALR del/+ bone marrow contains more phenotypically defined HSCs, and these cells exhibit increased proliferation in vitro, but the long term in vivo repopulating activity of CALR del/+ bone marrow is normal.
Homozygosity for CALR mutation (CALR del/del ) results in severe thrombocytosis and development of myelofibrosis
To assess the pathological consequences of homozygous expression of mutant calreticulin, Figure 6B ). At 4 months post transplantation, secondary transplants were performed, analysis showed that CALR del/del cells exhibit similar competitive repopulating capacity in the secondary recipients ( Figure 6C ). Together, these data demonstrate that CALR del/del bone marrow contains strikingly expanded phenotypically defined HSCs, but the long term in vivo repopulating activity of CALR del/del bone marrow are comparable to the wildtype controls.
DISCUSSION
In this paper, we describe a knock-in mouse model of the most common CALR mutation, an approach that allows us to explore the consequences of mutant CALR without the confounding effects of additional mutations present in samples from MPN patients. The targeting strategy was chosen to result in expression of a murine CALR protein in which the wild type C-terminus is replaced by the mutant human C-terminus found in MPN patients. Following Cre-mediated recombination, the mutant transcript is expressed under the control of the full complement of endogenous CALR regulatory elements.
Heterozygous CALR del/+ mice develop an ET-like phenotype with marked thrombocytosis, increased megakaryopoiesis and abnormal bone marrow megakaryocyte morphology.
Hemoglobin and red cell levels were normal and there was no increased reticulin staining in the bone marrow. The results contrast with the phenotype of JAK2V617F knock-in mice in which platelets, hemoglobin and leukocytes are all elevated and the bone marrow contains increased erythroid, myeloid and megakaryocytic progenitors. [24] [25] [26] [27] Moreover, these differing phenotypes are consistent with what is observed in JAK2-mutant compared to CALR-mutant MPN patients. The isolated thrombocytosis seen in CALR del/+ mice resembles that seen in CALR-mutant ET patients and, compared to JAK2-mutant ET patients, those carrying a CALR mutation have higher platelet levels with lower levels of hemoglobin and white cells. [28] [29] [30] [31] Furthermore, the effect of mutant CALR on platelet reactivity was different from that previously observed with JAK2 mutant cells. 23 Whilst the former showed normal responses to platelet agonists, JAK2 mutant platelets were hyper-reactive. These results are in keeping with the increased thrombosis rate observed in patients bearing JAK2 mutations. 30 Homozygosity for CALR mutations has been observed in patients with ET, 13,31,32 but its pathogenetic consequences are unclear. Our results demonstrate that homozygosity for mutant CALR causes extreme thrombocytosis associated with increased white cell counts, reduced hemoglobin levels, splenomegaly and increased levels of bone marrow reticulin, a constellation of features that resemble myelofibrotic transformation of ET. This phenotype contrasts with that seen in mice homozygous for JAK2V617F, which show extreme elevation of hemoglobin levels and a fall in platelet counts relative to mice heterozygous for JAK2V617F. 33 Together, our data demonstrate clear differences in the consequences of CALR and JAK2 mutations, and that these differences are more pronounced in the homozygous setting.
Our results accord with observations made using retroviral transplants or transgenic mice expressing the human mutant CALR. 14, 17, 18 Both approaches resulted in thrombocytosis and megakaryocytic hyperplasia, but myelofibrosis was only seen in mice harboring retroviral constructs, 17 perhaps reflecting varying levels of expression achieved by these different approaches. This concept is consistent with our finding of myelofibrosis is in CALR del/del but not in CALR del/+ mice.
Our results shed light on the role of mutant CALR within the HSC compartment. Bone marrow transplant studies demonstrated that the ET-like phenotype seen in CALR del/+ mice could be propagated in both primary and secondary recipients. These results demonstrate that CALRmutant long-term repopulating HSCs are able to give rise to features of ET even in secondary recipients where chimerism levels were reduced to 60%. These observations accord with studies of patients with CALR-mutant ET, which showed that the CALR mutation is present in highly purified HSCs. 6 Moreover, analyses of individual hematopoietic colonies showed that the CALR mutation was present in the first mutant phylogenetic node in all 5 patients studied, indicating that it was likely to be an initiating mutation in these patients. 6 However, our data show that mutant CALR does not confer a competitive HSC advantage in serial transplants in either heterozygous or homozygous settings. This result is consistent with the report of a transgenic mouse model which concluded that HSCs expressing mutant CALR exhibited normal self-renewal. 18 In a retroviral transplant model, phenotypic GFP + LSK and GFP + SLAM LSK cells expanded over time in primary recipient mice. 17 However, secondary transplants were not performed and therefore the impact on long term HSC function remains unclear. Both transgenic and retroviral approaches are known to result in dysregulated expression, both in terms of transcript levels and pattern of expression, which may contribute to the distinct phenotypes.
It is interesting that our knock-in mutant CALR mice (and three independent mutant JAK2 knockin mice 20, 24, 34, 35 ) all show no HSC advantage in serial transplantation studies, despite mutant CALR (or mutant JAK2) being found as a sole driver mutation in a substantial proportion of MPN patients. There are several potential explanations (not mutually exclusive) for this apparent conundrum: (i) genetic background may cooperate with mutant CALR -there is mounting evidence that genetic background influences HSC function in mice 36, 37 and also the development of both MPNs [38] [39] [40] and clonal hematopoiesis 41 ; (ii) unidentified somatic driver mutations may cooperate with mutant CALR -it seems unlikely that many additional coding mutations remain to be discovered, but there is much less known about the role of somatic non-coding mutations affecting regulatory elements in tumors [42] [43] [44] ; (iii) age-related changes affecting the microenvironment (eg niche or inflammatory signaling) may explain the association of MPNs with increasing age [45] [46] [47] ; and (iv) lineage tracing studies suggest that steady state hematopoiesis is supported by long-lived progenitors that may not read out in transplantation assays. 48, 49 Levels of the mutant protein were much lower than levels of WT protein, consistent with previous findings that the mutant protein is unstable 50, 51 and less abundant compared to WT controls in a retroviral expression model. 17 We also noted that, in HSPCs from heterozygous knock-in mice, mutant transcripts were expressed at lower levels (mean 68%) relative to WT transcripts. We considered the possibility that this might reflect a technical problem with our construct and explain the lack of a clonal advantage. Although our data do not formally exclude this scenario, we believe this is highly unlikely for multiple reasons: (1) The knock-in construct gives rise to strong HSC, progenitor, megakaryocytic and platelet phenotypes. HSC, progenitor and platelet numbers are similar to or higher than those seen in the retroviral or transgenic mouse models. THPO receptor. 14, 15 Our mouse model provides a powerful tool to further dissect the mechanisms by which mutant CALR contributes to MPN pathogenesis.
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